Canada Markets close in 3 hrs 22 mins

Vir Biotechnology, Inc. (VIR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
41.41-0.99 (-2.33%)
As of 12:36PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close42.40
Open41.27
Bid41.57 x 900
Ask41.86 x 800
Day's Range41.27 - 42.94
52 Week Range16.09 - 75.00
Volume457,695
Avg. Volume1,030,609
Market Cap5.275B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Biotech Stock Roundup: Updates From REGN, GILD & VIR, CVAC Teams Up With BAYRY
    Zacks

    Biotech Stock Roundup: Updates From REGN, GILD & VIR, CVAC Teams Up With BAYRY

    The biotech sector was in focus last week with guidance updates from quite a few biotechs like Gilead (GILD). Additionally, updates on coronavirus treatments from Regeneron (REGN) and Vir (VIR) were in focus.

  • Vir Biotech, Glaxo to Begin Study on Second COVID-19 Therapy
    Zacks

    Vir Biotech, Glaxo to Begin Study on Second COVID-19 Therapy

    Vir Biotechnology (VIR) and its British partner, Glaxo announces agreement umder which they will evaluate their second coronavirus therapeutic candidate.

  • Why Vir Biotechnology Stock Vaulted Higher Today
    Motley Fool

    Why Vir Biotechnology Stock Vaulted Higher Today

    Shares of Vir Biotechnology (NASDAQ: VIR) were vaulting 12.8% higher as of 3:07 p.m. EST on Tuesday. The big jump came after the company announced news about separate collaborations with Gilead Sciences (NASDAQ: GILD) and GlaxoSmithKline (NYSE: GSK). Vir and Gilead plan to work together on a phase 2 study evaluating Vir's VIR-2218 with Gilead's selgantolimod in treating individuals infected with the hepatitis B virus (HBV).